432 related articles for article (PubMed ID: 17146064)
1. Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs.
Paltiel AD; Walensky RP; Schackman BR; Seage GR; Mercincavage LM; Weinstein MC; Freedberg KA
Ann Intern Med; 2006 Dec; 145(11):797-806. PubMed ID: 17146064
[TBL] [Abstract][Full Text] [Related]
2. Expanded screening for HIV in the United States--an analysis of cost-effectiveness.
Paltiel AD; Weinstein MC; Kimmel AD; Seage GR; Losina E; Zhang H; Freedberg KA; Walensky RP
N Engl J Med; 2005 Feb; 352(6):586-95. PubMed ID: 15703423
[TBL] [Abstract][Full Text] [Related]
3. The cost-effectiveness and population outcomes of expanded HIV screening and antiretroviral treatment in the United States.
Long EF; Brandeau ML; Owens DK
Ann Intern Med; 2010 Dec; 153(12):778-89. PubMed ID: 21173412
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy.
Sanders GD; Bayoumi AM; Sundaram V; Bilir SP; Neukermans CP; Rydzak CE; Douglass LR; Lazzeroni LC; Holodniy M; Owens DK
N Engl J Med; 2005 Feb; 352(6):570-85. PubMed ID: 15703422
[TBL] [Abstract][Full Text] [Related]
5. The cost-effectiveness of preexposure prophylaxis for HIV prevention in the United States in men who have sex with men.
Juusola JL; Brandeau ML; Owens DK; Bendavid E
Ann Intern Med; 2012 Apr; 156(8):541-50. PubMed ID: 22508731
[TBL] [Abstract][Full Text] [Related]
6. Screening for Chlamydia trachomatis in women 15 to 29 years of age: a cost-effectiveness analysis.
Hu D; Hook EW; Goldie SJ
Ann Intern Med; 2004 Oct; 141(7):501-13. PubMed ID: 15466767
[TBL] [Abstract][Full Text] [Related]
7. The cost-utility of screening for depression in primary care.
Valenstein M; Vijan S; Zeber JE; Boehm K; Buttar A
Ann Intern Med; 2001 Mar; 134(5):345-60. PubMed ID: 11242495
[TBL] [Abstract][Full Text] [Related]
8. Portfolios of biomedical HIV interventions in South Africa: a cost-effectiveness analysis.
Long EF; Stavert RR
J Gen Intern Med; 2013 Oct; 28(10):1294-301. PubMed ID: 23588668
[TBL] [Abstract][Full Text] [Related]
9. Summaries for patients. Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs.
Ann Intern Med; 2006 Dec; 145(11):I30. PubMed ID: 17146061
[No Abstract] [Full Text] [Related]
10. How much should we pay for a new HIV diagnosis? A mathematical model of HIV screening in US clinical settings.
Farnham PG; Sansom SL; Hutchinson AB
Med Decis Making; 2012; 32(3):459-69. PubMed ID: 22247422
[TBL] [Abstract][Full Text] [Related]
11. Visual screening for malignant melanoma: a cost-effectiveness analysis.
Losina E; Walensky RP; Geller A; Beddingfield FC; Wolf LL; Gilchrest BA; Freedberg KA
Arch Dermatol; 2007 Jan; 143(1):21-8. PubMed ID: 17224538
[TBL] [Abstract][Full Text] [Related]
12. Use of genotypic resistance testing to guide hiv therapy: clinical impact and cost-effectiveness.
Weinstein MC; Goldie SJ; Losina E; Cohen CJ; Baxter JD; Zhang H; Kimmel AD; Freedberg KA
Ann Intern Med; 2001 Mar; 134(6):440-50. PubMed ID: 11255519
[TBL] [Abstract][Full Text] [Related]
13. Routine human immunodeficiency virus testing: an economic evaluation of current guidelines.
Walensky RP; Weinstein MC; Kimmel AD; Seage GR; Losina E; Sax PE; Zhang H; Smith HE; Freedberg KA; Paltiel AD
Am J Med; 2005 Mar; 118(3):292-300. PubMed ID: 15745728
[TBL] [Abstract][Full Text] [Related]
14. The cost-effectiveness of symptom-based testing and routine screening for acute HIV infection in men who have sex with men in the USA.
Juusola JL; Brandeau ML; Long EF; Owens DK; Bendavid E
AIDS; 2011 Sep; 25(14):1779-87. PubMed ID: 21716076
[TBL] [Abstract][Full Text] [Related]
15. HIV screening via fourth-generation immunoassay or nucleic acid amplification test in the United States: a cost-effectiveness analysis.
Long EF
PLoS One; 2011; 6(11):e27625. PubMed ID: 22110698
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of universal compared with voluntary screening for human immunodeficiency virus among pregnant women in Chicago.
Immergluck LC; Cull WL; Schwartz A; Elstein AS
Pediatrics; 2000 Apr; 105(4):E54. PubMed ID: 10742375
[TBL] [Abstract][Full Text] [Related]
17. Clinical impact and cost-effectiveness of expanded voluntary HIV testing in India.
Venkatesh KK; Becker JE; Kumarasamy N; Nakamura YM; Mayer KH; Losina E; Swaminathan S; Flanigan TP; Walensky RP; Freedberg KA
PLoS One; 2013; 8(5):e64604. PubMed ID: 23741348
[TBL] [Abstract][Full Text] [Related]
18. The cost-effectiveness of screening the U.S. blood supply for West Nile virus.
Custer B; Busch MP; Marfin AA; Petersen LR
Ann Intern Med; 2005 Oct; 143(7):486-92. PubMed ID: 16204161
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of screening for HIV in primary care: a health economics modelling analysis.
Baggaley RF; Irvine MA; Leber W; Cambiano V; Figueroa J; McMullen H; Anderson J; Santos AC; Terris-Prestholt F; Miners A; Hollingsworth TD; Griffiths CJ
Lancet HIV; 2017 Oct; 4(10):e465-e474. PubMed ID: 28768604
[TBL] [Abstract][Full Text] [Related]
20. Universal Rapid Human Immunodeficiency Virus Screening at Delivery: A Cost-Effectiveness Analysis.
Scott RK; Crochet S; Huang CC
Infect Dis Obstet Gynecol; 2018; 2018():6024698. PubMed ID: 29731602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
